Skip to main content
. Author manuscript; available in PMC: 2016 Sep 2.
Published in final edited form as: Adv Drug Deliv Rev. 2014 May 22;81:128–141. doi: 10.1016/j.addr.2014.05.009

Fig. 3.

Fig. 3

Strategies for miRNA delivery In vivo. Many strategies such as modified miRNA antagonists or miRNA mimics, viral vectors, inorganic or organic non-viral delivery systems have been established for delivery of miRNAs for cancer therapy. miRNA antagonists modified with LNAs bind to the targeted miRNAs with high affinity (A). Vectors encoding miRNA antagonists or miRNA mimics can be carried by viral vectors for In vivo delivery (B). Silica nanoparticles modified with GD2 antibody specifically deliver miRNAs into tumors overexpressing GD2 (C). miRNAs can be encapsulated in organic non-viral delivery systems such as PLGA, PEI (D) and liposome based nanoparticle (E) that are modified either with ligands or with antibodies for tumor-targeted delivery (F).